UCB (OTCMKTS:UCBJF) Hits New 12-Month High - Here's Why

Key Points

• UCB SA's stock reached a new 52-week high at $224.64 and has seen a notable increase of 8.5% recently.
• Morgan Stanley has upgraded UCB shares to an "overweight" rating as part of their recent analysis.
• The company's primary offerings include treatments for various neurology and immunology diseases, showcasing a broad range of pharmaceutical products.

UCB SA (OTCMKTS:UCBJF - Get Free Report)'s share price reached a new 52-week high on Tuesday . The stock traded as high as $224.64 and last traded at $224.64, with a volume of 1 shares trading hands. The stock had previously closed at $207.00.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley raised shares of UCB to an "overweight" rating in a research note on Monday, June 23rd.

UCB Stock Up 0.5%

The business has a 50-day moving average of $200.34 and a 200-day moving average of $185.18. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.